Nexgenrx Stock Performance
| NXG Stock | CAD 0.22 0.02 10.00% |
The company secures a Beta (Market Risk) of -0.44, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NexgenRX are expected to decrease at a much lower rate. During the bear market, NexgenRX is likely to outperform the market. NexgenRX has an expected return of -0.0766%. Please make sure to verify NexgenRX downside variance, as well as the relationship between the kurtosis and day typical price , to decide if NexgenRX performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days NexgenRX has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, NexgenRX is not utilizing all of its potentials. The recent stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Forward Dividend Yield 0.0455 | Payout Ratio 0.2326 | Forward Dividend Rate 0.01 | Dividend Date 2024-01-04 | Ex Dividend Date 2023-12-28 |
1 | Closing Bell Nexgenrx Inc down on Friday - The Globe and Mail | 02/09/2024 |
2 | Closing Bell Nexgenrx Inc down on Monday - The Globe and Mail | 04/22/2024 |
| Begin Period Cash Flow | 1.8 M |
NexgenRX |
NexgenRX Relative Risk vs. Return Landscape
If you would invest 25.00 in NexgenRX on February 4, 2024 and sell it today you would lose (3.00) from holding NexgenRX or give up 12.0% of portfolio value over 90 days. NexgenRX is currently producing negative expected returns and takes up 5.1031% volatility of returns over 90 trading days. Put another way, 45% of traded stocks are less volatile than NexgenRX, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NexgenRX Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NexgenRX's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NexgenRX, and traders can use it to determine the average amount a NexgenRX's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.015
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NXG |
Estimated Market Risk
| 5.1 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average NexgenRX is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NexgenRX by adding NexgenRX to a well-diversified portfolio.
NexgenRX Fundamentals Growth
NexgenRX Stock prices reflect investors' perceptions of the future prospects and financial health of NexgenRX, and NexgenRX fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NexgenRX Stock performance.
| Return On Equity | -0.0401 | ||||
| Return On Asset | -0.0032 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 15.75 M | ||||
| Shares Outstanding | 70.53 M | ||||
| Price To Earning | 76.67 X | ||||
| Price To Book | 2.73 X | ||||
| Price To Sales | 1.20 X | ||||
| Revenue | 13.85 M | ||||
| Gross Profit | 9.81 M | ||||
| EBITDA | 1.1 M | ||||
| Net Income | (331.97 K) | ||||
| Cash And Equivalents | 675.31 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 4.36 M | ||||
| Debt To Equity | 214.60 % | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | 1.28 M | ||||
| Total Asset | 30.2 M | ||||
| Retained Earnings | (2.14 M) | ||||
About NexgenRX Performance
To evaluate NexgenRX Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when NexgenRX generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare NexgenRX Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand NexgenRX market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents NexgenRX's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans in Canada. NexgenRx Inc. was founded in 2003 and is headquartered in Toronto, Canada. NEXGENRX INC operates under Health Care Plans classification in Canada and is traded on TSX Venture Exchange.Things to note about NexgenRX performance evaluation
Checking the ongoing alerts about NexgenRX for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NexgenRX help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NexgenRX generated a negative expected return over the last 90 days | |
| NexgenRX has high historical volatility and very poor performance | |
| NexgenRX has some characteristics of a very speculative penny stock | |
| NexgenRX has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company has accumulated 4.36 M in total debt with debt to equity ratio (D/E) of 214.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. NexgenRX has a current ratio of 0.88, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist NexgenRX until it has trouble settling it off, either with new capital or with free cash flow. So, NexgenRX's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NexgenRX sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NexgenRX to invest in growth at high rates of return. When we think about NexgenRX's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 13.85 M. Net Loss for the year was (331.97 K) with profit before overhead, payroll, taxes, and interest of 9.81 M. | |
| About 37.0% of NexgenRX outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Closing Bell Nexgenrx Inc down on Monday - The Globe and Mail |
- Analyzing NexgenRX's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NexgenRX's stock is overvalued or undervalued compared to its peers.
- Examining NexgenRX's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NexgenRX's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NexgenRX's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NexgenRX's stock. These opinions can provide insight into NexgenRX's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NexgenRX. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for NexgenRX Stock analysis
When running NexgenRX's price analysis, check to measure NexgenRX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NexgenRX is operating at the current time. Most of NexgenRX's value examination focuses on studying past and present price action to predict the probability of NexgenRX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NexgenRX's price. Additionally, you may evaluate how the addition of NexgenRX to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Correlations Find global opportunities by holding instruments from different markets |